Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice by unknown
Animal models of autoimmunity, particularly mouse
LA models, have been invaluable toolsto the study ofhuman
SLE (1) . Both share serologic and pathologic abnormalities,
although human and murine SLE may differ in manner of
expression (2). Since the etiology of both human and murine
SLE remains unknown, it remains to be determined whether
they share common etiologic factors and if the conclusions
from the study of murine SLE will be directly applicable to
the human counterpart. The recent report oflong-term en-
graftment of human lymphoid cells, particularly functional
human PBL into SCID mice (3, 4), prompted us to study
the effect of the PBL transfer from SLE patients into SCID
mice (SCID-hu-SLE), in an attempt to create a human SLE
model that couldbe manipulated within the context of a lab-
oratory animal.
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Summary
To study the role of peripheral blood leukocytes (PBL) in the pathogenesis of human systemic
lupus erythematosus (SLE), we transferred PBL from 5 SLE patients into 15 severe combined
immunodeficiency (SCID) mice. Such reconstituted mice showed long-term presence of auto-
antibodies characteristic of the donor in their sera, as well as human immunoglobulin deposition,
and in some cases mouse C3, in the renal glomeruli. SCID mice repopulated with PBLs from
normal donors do not develop serologic abnormalities or immunodeposits. It is concluded that
humanSLE serology and some associated renalchanges can be reproduced solely by PBL transferred
from afflicted patients, and that SCID-human-SLE mice may serve as an in vivo laboratory model
for the study of human SLE.
Cell Transfer.
￿
PBL from healthy donors or SLE patients were
isolated by Ficoll Hypaque separation. Within 6 h ofdrawing, 15
x 106 PBL were injected intraperitoneally into 8-wk-old nonleaky
C.B-17 scid/scid(SCID) mice. A successfulreconstitution was con-
sidered if the level of human IgG in the mouse was >1,000 /4g/ml
in 90 d or less after the cell transfer. We included one SCID-hu-
SLE mouse (No. 10, see Results and Discussion) that, although
not fulfilling our criteria for a good reconstitution, displayed a high
antinuclear antibody (ANA) titer.
Human Ig Level Determination. Human IgG and IgM were
quantifiedas described using a modification of the particle concen-
tration fluorescence immunoassay procedure of Jolley et al. (5).
Briefly, polystyrene particles previously adsorbed with a polyva-
lent, mouse-absorbed, goat anti-human Ig (Caltag, South San
Francisco, CA) were incubated with serum samples or respective
standards of human IgG, Fx II (Pentex 46), or human IgM
(Calbiochem-Behring Corp., San Diego, CA). Bound IgG or IgM
were revealed using an Fc-specific goat anti-human IgG, or a goat
anti-human IgM conjugated to FITC (Caltag), respectively. These
manipulations were performed in special assay plates using an au-
tomated fluorescent concentrated analyzer (Pandex Laboratories,
Inc., Mundelein, IL).
Human ANA Titer Determination.
￿
Serum human ANA titers
were determined using HEP-2 cells as a substrate (Bion Enterprises,
Ltd., Park Ridge, IL), and specific human ANA were revealed using
a Burro anti-human total Ig conjugated to fluorescein (Kallestad
Diagnostics, Austin, TX). The human ANA isotypes were deter-
minedusing the same procedure; the ANA were revealed with the
FITC-conjugated antibodies described in the human Ig level deter-
mination section. Slides were examined under an Olympus BH2-
RFL microscope equipped with a reflected light fluorescence illu-
minator (Olympus, Tokyo, Japan).
Histology.
￿
Tissues were fixed in Bouins fixative, paraffin em-
bedded, and 4-1m sections were stained with periodic acid Schiff
(A). Alternatively, unfixed frozen sections were incubated with a
Burro anti-human total Ig conjugated to fluorescein (Kallestad Di-
agnostics) (B), a goat anti-mouse C3 (Cappel Laboratories, Mal-
vern, PA), or an anti-human C3, and examined under reflected
light fluorescence.
Results and Discussion
15 SCID mice were injected intraperitoneally with 15 x
106 PBL from 5 SLE patients (SCID-hu-SLE), and 9 mice
were injected with 15 x 106 PBL from 3 normal donors
(SCID-hu), and bled periodically thereafter. As depicted in
Table 1, such reconstituted mice showed long-term presence
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mice and the majority of patient ANA were positive for IgG only.
The exceptions were donor 4 and mouse 2, who presented equal re-
. .
￿
donor
.
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titer (1:100) . The ANA titers of 29 SCID-hu mice repopulated with
PBL from three different donors were 1:10 in 5 mice, 1:2 in 7, and
negative at 1:2 in 17 .
Transfer of Human Systemic Lupus Erythematosus in SCID Mice
Determination of human IgG/IgM levels 15, 30, 60, 90, 120, 150, 180, and 270 d after engraftment of human PBL . -, dead .
` SCID-hu-SLE mice 9 and 10 developed human lymphoma, which caused their death . These two mice have not been included in the histolo-
gy/immunofluorescent kidney results .
t For comparison the mean human IgG/IgM level of nine SCID-hu mice is included .
ofhuman IgG, reachingmaximum levels -2 mo after transfer
and then gradually declining over the next 4-7 mo, although
great individual variety exists. Atmaximum values, thehuman
IgG levels in the mice were approximately one-fifth of the
normal human levels . The evolution of human IgM in the
SCID recipient was more variable than that ofhuman IgG,
as illustrated in Table 1 .
FRCS analysis on PBL from SCID-hu mice demonstrates
the presence ofhuman B and T cells (representing up to 15%
of the total PBMC population) . Among T cells, the ratio
of CD4+CD8 -/CD4 -CD8+ at 1 and 2 mo post-engraft-
ment are 3:1, and 1:2, respectively (data not shown) . Human
ANA titers reflecting those of the SLE donors were found
in the 15 SCID-hu-SLE mice, while little or no such anti-
body was found in 29 SCID-hu mice, comprising the 9
depicted in Table 1 (Fig. l, legend) . ThisANA must have
been produced by the transferred cells in the murine host
since the cells had been well washed to eliminate contaminating
antibody, and since it persisted well beyond the time expected
for passive antibody transfer (half-life ofhuman IgG andIgM
in the SCID recipient are 184 and 108 h, respectively; data
not shown) . The SCID-hu-SLE mice had a ratio of ANA
titers to human IgG levels of the same order of magnitude
as the SLE patient donors, and, as in the donors, the ANA
autoantibodies are primarily ofthe IgG isotype (Fig. l, legend) .
Table 1 . Quantitation ofHuman IgG and IgM Levels (,ug/ml) in SCID-hu-SLE and SCID-hu Mice
SCID-hu
SLE D15 D30 D60 D90 D120 D150 D180 D270
No . 1 122/2.4 703/3.6 1,277/14.0 1,320/8.9 2,165/78.0 959/4.0 573/1.2 363/0.3
2 253/2.8 1,398/22.0 1,710/66.0 1,282/47 .0 992/27.0 719/13.0 594/9.2 265/2.2
3 185/3.0 760/9.6 865/56.0 1,222/120.0 917/105 .0 - - -
4 265/1 .8 1,065/6.9 2,041/112.0 2,701/249.0 1,689/101 .0 - - -
5 182/2.8 1,657/32.0 3,002/283 .0 2 .944/133 .0 1,200/7.8 1,211/35 .0 982/16.0 484/2.0
6 932/16.0 1,968/11 .0 1,359/10 .0 1,210/5.8 1,004/2.9 573/2.2 744/2.1 -
7 3,222/41.0 3,191/18 .0 2,691/38.0 2,548/42 .0 1,662/15 .0 1.007/11 .0 1,120/8.5 261/2.2
8 3,557/35.0 2,488/22.0 2,714/71.0
9 3,555/21.0 2,148/8.4 2,419/90 .0 855/1,984-
10 164/0.7 247/0.3 298/11.0 261/1,004* 136/2,803' - -
11 2,858/54.0 2,337/12.0 3,512/13.0 1,498/9.7 762/5 .4 393/2.6 248/1.2
12 2,288/55.0 2427/15.0 2,569/7.6 2,237/7.1 1,476/19 .0 2,168/36 .0 1,342/24 .0
13 1,863/36.0 2,045/18.0 2,050/11.0 1,121/6.0 566/2.9 334/3 .1 207/9 .2
14 1,160/14.0 1,375/20.0 1,654/31.0 705/7.8 492/4.2 467/2.2 195/1 .1
15 1,827/34 .0 1,897/7.9 -
SCID-hut 884/3.4 918/13.5 1,643/17 .2 1,776/20 .6 1,394/22 .2 1,037/4.6 775/7.3 118/0.5Figure 2 .
￿
Fluorescence photomicrograph of glomeruli of SCID-hu-
SLE mice 224 d after transfer of PBL (AC), and age and IgG level-
matched SCID-hu mice (B,D) stained with a Burro anti-human Ig
(A,B), or a goat anti-mouse C3 (C,D) . Ig and mouse C3 deposits
are seen in a pattern consistent with capillary wall and mesangial lo-
calization.
It appears that the cells transferred from the peripheral blood
of afflicted patients have already undergone IgM to IgG
switching in their ANA production . Such IgG anti-DNA
autoantibodies are believed to be the primary pathogens in
mice as well as in humans (6, 7) .
The persistence ofantibody synthesis by autoreactive clones
in the SCID-hu-SLE model might be secondary to the pres-
ence ofhuman or murine antigen(s) . The additional possi-
bility that this B cell population is polyclonally stimulated
in this model cannot be excluded. ANA titers in some SCID-
hu-SLE mice were maintained up to 7 mo, although the
majority decreased by 3-4 mo post-engraftment . Although
there is variabilitybetween individual mice, the general ratio
of ANA titer vs. human IgG decreased with time. This de-
creasedANA production may reflect the lifespan of the B
cell autoreactive clones in.the model, and/or the termination
ofB cell stimulation in the murine reconstituted human im-
mune system . The progressive loss of CD4+CD8- human
T cell subset in SCID-hu recipients, strongly implicated in the
stimulation of IgG autoantibody-producing B cells in human
and mouse (8, 9), might play an important role in the auto-
antibody decline in this model .
Autoantibodies in SLE patients form immune complexes
detectable in the circulation and target organs, such as kidneys
(2) . We examined seven kidney biopsies from SCID-hu-SLE
mice, and four fromSCID-hu mice. Conventional histologic
examination revealed no alteration in the SCID-hu model,
and only minimal mesangial proliferation in the SCID-hu-
SLE model (data not shown) . Immunofluorescence studies
on six of seven SCID-hu-SLE kidney biopsies showed the
presence of granular deposits of human Ig in a pattern sug-
gestive of mesangial and capillary loop distribution (Fig. 2
A) . Half of those kidneys positive for human Ig were also
positive for mouseC3 (Fig . 2 C) . SCID-hu mice do not present
such Ig or mouse C3 deposits in their glomeruli (Fig. 2, B
and D) . All kidneys examined were negative for human C3
(data not shown) . The lack, or minimal activation of, this
important effector pathway of the immune response, as well
as the relatively short time of autoantibody production, might
explain the paucity of lesions seen on conventional histology,
as well as the absence of significant proteinuria or elevated
BUN level in SCID-hu-SLE mice (data not shown) .
In summary, we report the first transfer of human SLE
serology and some glomerular pathology into SCID mice .
This new in vivo model expands our potential to directly
evaluate the influence of cellular and humoral functions in
the progression of this disease. In addition, this ability to
transfer PBL from one donor into multiple mice allows us
to compare various potential therapies simultaneously on the
disease-producing cells of a single patient .
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